octgt guidance document update rachael anatol, ph.d. associate director for policy-new legislation...
DESCRIPTION
Good Guidance Practices (GGPs) FDA’s policies and procedures for developing, issuing, and using guidance documents Require FDA to publish yearly guidance agenda Call for public participationTRANSCRIPT
OCTGT Guidance Document Update
Rachael Anatol, Ph.D.Associate Director for Policy-New
LegislationFebruary 26, 2014
Outline• Good Guidance Practices• Guidance basics• Guidances issued by OCTGT since 2009• OCTGT 2014 Guidance Agenda
Good Guidance Practices (GGPs)• FDA’s policies and procedures for
developing, issuing, and using guidance documents
• Require FDA to publish yearly guidance agenda
• Call for public participation
Guidance Document Basics• Documents prepared for FDA,
applicants/sponsors, and the public that describe FDA’s interpretation of or policy on a regulatory issue
• First means of communication to a broad audience
• Not legally binding
Guidance Document Topics• Design, production, labeling, promotion,
manufacturing, and testing of regulated products
• Processing, content, and evaluation or approval of submissions
• Inspection and enforcement policies
OCTGT Draft Guidance Documents Published Since Last Update
• Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) ; 2013
• Draft Guidance for Industry: Use of Donor Screening Tests to Test Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for Infection with Treponema pallidum (Syphilis) ; 2013
• Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; 2013
• Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System; 2013
• Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System; 2013
OCTGT Final Guidance Documents Published Since Last Update
• Preclinical Assessment of Investigational Cellular and Gene Therapy Products; 2013
• Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage; 2011
• Clinical Considerations for Therapeutic Cancer Vaccines; 2011• Potency Tests for Cellular and Gene Therapy Products; 2011• Current Good Tissue Practice (CGTP) and Additional
Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); 2011
• Class II Special Controls Guidance Document: Cord Blood Processing System and Storage Container; 2011
• Cellular Therapy for Cardiac Disease; 2010• Considerations for Allogeneic Pancreatic Islet Cell Products;
2009
OCTGT Guidances on 2014 CBER Guidance Agenda
• Draft Guidance for Industry: Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products
• Draft Guidance for Industry: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue Based Products
• Final Guidance for Industry: Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System
• Final Guidance for Industry: Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System
OCTGT Contact Information• Rachael Anatol: [email protected] • Regulatory Questions:
Contact the Regulatory Management Staff in OCTGT at [email protected] or [email protected] or by calling (301) 827-6536
• OCTGT Learn Webinar Series: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/ucm232821.htm
9
Public Access to CBERCBER website:http://www.fda.gov/BiologicsBloodVaccines/default.htm.
Cellular and gene therapy guidances:http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/
default.htm
Tissue guidances:http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/default.htm
All biologics guidance and CBER 2014 guidance agenda:http://www.fda.gov/biologicsbloodVaccines/GuidanceComplianceRegulatoryInformation/guidances/default.htm
Consumer Affairs Branch (CAB) Email: [email protected]
Phone: 301-827-3821
Manufacturers Assistance & Technical Training Branch (MATTB)Email: [email protected]
Phone: 301-827-4081
Follow us on Twitter https://www.twitter.com/fdacber